Irhythm Technologies (IRTC) Gets a Hold from Goldman Sachs
In a report released today, David Roman from Goldman Sachs maintained a Hold rating on Irhythm Technologies, with a price target of $147.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Roman is an analyst with an average return of -4.9% and a 37.65% success rate. Roman covers the Healthcare sector, focusing on stocks such as Omada Health, Inc., Boston Scientific, and Insulet.
Irhythm Technologies has an analyst consensus of Strong Buy, with a price target consensus of $201.45.
Based on Irhythm Technologies’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $208.89 million and a net profit of $5.58 million. In comparison, last year the company earned a revenue of $164.33 million and had a GAAP net loss of $1.33 million
Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRTC in relation to earlier this year. Last month, Quentin Blackford, the President & CEO of IRTC sold 13,813.00 shares for a total of $1,774,141.72.
Read More on IRTC:
